Tumour treating fields therapy for glioblastoma: current advances and future directions

Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults and continues to portend poor survival, despite multimodal treatment using surgery and chemoradiotherapy. The addition of tumour-treating fields (TTFields)—an approach in which alternating electrical fields exert biophys...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	British journal of cancer Ročník 124; číslo 4; s. 697 - 709
Hlavní autoři:	Rominiyi, Ola, Vanderlinden, Aurelie, Clenton, Susan Jane, Bridgewater, Caroline, Al-Tamimi, Yahia, Collis, Spencer James
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London Nature Publishing Group UK 16.02.2021 Nature Publishing Group
Témata:	631/67/1922 639/766 692/4028/67/1059/485 692/4028/67/1059/602 692/4028/67/1059/99 Animals Biomedical and Life Sciences Biomedicine Brain cancer Brain Neoplasms - pathology Brain Neoplasms - therapy Brain tumors Cancer Cancer Research Cell permeability Cell proliferation Chemoradiotherapy Chemotherapy Clinical trials Clinical Trials, Phase III as Topic DNA repair Drug Resistance Electric fields Electric Stimulation Therapy - methods Epidemiology Glioblastoma Glioblastoma - pathology Glioblastoma - therapy Humans Mesothelioma Molecular Medicine Oncology Radiation therapy Randomized Controlled Trials as Topic Review Review Article Surgery
ISSN:	0007-0920, 1532-1827, 1532-1827
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults and continues to portend poor survival, despite multimodal treatment using surgery and chemoradiotherapy. The addition of tumour-treating fields (TTFields)—an approach in which alternating electrical fields exert biophysical force on charged and polarisable molecules known as dipoles—to standard therapy, has been shown to extend survival for patients with newly diagnosed GBM, recurrent GBM and mesothelioma, leading to the clinical approval of this approach by the FDA. TTFields represent a non-invasive anticancer modality consisting of low-intensity (1–3 V/cm), intermediate-frequency (100–300 kHz), alternating electric fields delivered via cutaneous transducer arrays configured to provide optimal tumour-site coverage. Although TTFields were initially demonstrated to inhibit cancer cell proliferation by interfering with mitotic apparatus, it is becoming increasingly clear that TTFields show a broad mechanism of action by disrupting a multitude of biological processes, including DNA repair, cell permeability and immunological responses, to elicit therapeutic effects. This review describes advances in our current understanding of the mechanisms by which TTFields mediate anticancer effects. Additionally, we summarise the landscape of TTFields clinical trials across various cancers and consider how emerging preclinical data might inform future clinical applications for TTFields.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23
ISSN:	0007-0920 1532-1827 1532-1827
DOI:	10.1038/s41416-020-01136-5